Presbyopia is one of the most well-known diseases of the eye, predominantly affecting the adult population after 50 years'. Due to hardening of the lens and failure of accommodative change, patients lose the ability to focus on near objects. This eye symptom is reported to be an early symptom of age-related nuclear cataract, and we have previously reported that hesperetin treatment could delay the onset of nuclear cataractogenesis induced by sodium selenite. In this study, we examined whether oral intake of α-glucosyl-hesperidin (G-Hsd), which has greater water solubility than hesperetin, could delay the onset of presbyopia. G-Hsd treatment protected lens elasticity, upregulated the mRNA expression of anti-oxidative enzymes like glutathione reductase and thioredoxin reductase 1 in the plasma and lens, and prevented premature cataract symptoms in selenite-induced cataract rat lens. Thus, the anti-presbyopic effects of G-Hsd were attributed, at least in part, to its antioxidant effects. G-Hsd represents the first oral treatment agent with anti-presbyopia and/or anti-cataract properties.
Keywords: Anti-Presbyopia effects; Anti-oxidants; Ascorbic acid: ROS, Reactive Oxygen Species: CAT; Catalase: SOD, Superoxide Dismutase; Hesperetin; Hst: Hesperetin: Hsd: Hesperidin: G-Hsd: α-glucosyl hesperidin: GSH, Reduced glutathione: AsA; Sclerosis of the lens; α-glucosyl hesperidin.
© 2020 The Authors.